| Currently Enrolling for: |
Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT.
The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg is superior to placebo at terminating episodes of PSVT in an outpatient setting.
Eligibility Criteria:
| Sex/Gender |
|
|---|
| Ages | 18 Years and older (Adult, Older Adult) |
|---|
| Accepts Healthy Volunteers | No |
|---|
Qualified participants may receive: |
|
Study-related medication at no cost |
|
Study-related medical exams at no cost |
|
No insurance is needed to participate. |
|
If you are interested in participating in our study, please fill out the form below or call us at (919) 267-5209.
Enroll Now: